戻る Agenda
Session 7 Track D: Publication Reviews to Achieve Quality
Session Chair(s)
Eileen Girten, MS
Medical Writing Therapeutic Area Lead
Pfizer, United States
Learning Objective : At the conclusion of this session, participants should be able to:
• Identify key components of publication development process leading to quality disclosures
• Explain expectations for author, editor, and contributor reviewer contributions
• Discuss the strategic delivery and importance of different review types, including writing, medical, statistics, and data integrity quality reviews
Speaker(s)
Faculty
David B. Clemow, PHD
Eli Lilly and Company, United States
Advisor, Scientific Communications Information Strategy
Faculty
Peter M. Fairfield, MBA
Eli Lilly & Company, United States
Scientific Communications Consultant
Faculty
Scott Patton
Stanford University, United States
Clinical Trials Regulatory Manager
Faculty
Darryl L'Heureux, PHD, MPHARM, MSC
Ambrx, Inc, United States
Director, Clinical Science, Medical Writing, and Publications
Faculty
Robin Whitsell
Whitsell Innovations, Inc., United States
President